MedTrace Logo

Deep Phenotyping in Patients With ALS

NCT02819765 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 32

Last updated 2021-12-16

No results posted yet for this study

Summary

This study aims to establish a biorepository and phenotyping database to investigate longitudinal changes in ALS subjects. Blood, including DNA and RNA, cerebrospinal fluid (CSF) and electrophysiologic measures will be collected every 6 months over 1 and a half years. The database and specimen repository will be made available to ALS researchers on a merit basis.

Conditions

  • ALS
  • Motor Neuron Disease

Sponsors & Collaborators

  • ALS Association

    collaborator OTHER

  • Barrow Neurological Institute

    lead OTHER

Principal Investigators

  • Shafeeq Ladha, MD · Barrow Neurological Institute

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-07
Primary Completion
2021-11-09
Completion
2021-11-09

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02819765 on ClinicalTrials.gov